SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13D/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13D - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13G - TC BioPharm (Holdings) plc (0001872812) (Subject)

SC 13D - TC BioPharm (Holdings) plc (0001872812) (Subject)

EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 10:00 am EST. Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provid

Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it now plans to host its shareholder update call on Tuesday, February 21, 2023, at 12:00 p.m. ET.  The call was originally scheduled for Monday, February 20, 2023, at 10:00 a.m. ET. Management intends to provide a comprehensive update on th

Conference Call to be held on Monday, February 20th, 2023 at 10:00 am ET EDINBURGH, Scotland, Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the company will host a shareholder update call on Monday, February 20th, 2023, at 10:00 am EST. Management intends to provide a comprehensive update on the Company's clinical trial plan for its allogeneic gamma delta therapeutic in oncology

4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

3 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

3 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

3 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

EDINBURGH, Scotland, Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex® Grant Program.  The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development an

EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm. "The ACHIEVE UK tria

TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchangeEDINBURGH, Scotland, Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange.  The since deleted rumor stated th

EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, United Kingdom and works closely with The Pirbright Institute, a leading ce

TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching processThe software could have additional applications across cell therapy for donor/patient matchingEDINBURGH, Scotland, Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the

Additional London-based clinic to increase enrolment velocityLeading hospital with extensive cell therapy and oncology trial experienceEDINBURGH, Scotland, Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial. Guys and St. Thomas is a London-based hospital with a leading oncology clinic and cell therapy clin

EDINBURGH, Scotland, Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City. Mr. Kobel plans to provide insight into the company's clinical trials as well as recent improvements to TC BioPharm's balance sheet.  For m

No TCB008-related Adverse Events seen in any of the re-start patients6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth doseEDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients. As previously stated, patients are eligible to receive up to 4 total doses of TCB und

EDINBURGH, Scotland, Sept. 9, 2024  /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) cells which the company expects will have applications in treating the gl

EDINBURGH, Scotland, Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) cells which the company expects will have applications in treating the glo

The Company's lead therapeutic will be available through a newly opened compassionate use programEDINBURGH, Scotland, May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK.

Shares of Zeta Global Holdings Corp. (NASDAQ:ZETA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and increased its second-quarter revenue guidance. Zeta Global posted GAAP loss of 23 cents per share, compared to market expectations for a loss of 25 cents per share. The company's quarterly sales came in at $194.947 million topping estimates of $187.112 million, according to data from Benzinga Pro. Zeta Global shares jumped 15.3% to $15.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers reAlpha Tech Corp (NASDAQ:AIRE) gained 65.8% to $1.42 in pre-market trading a

TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years. Each ADS represents twenty ordinary shares of the Company. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately £3.1 million, prior to deducting plac

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million. Outset Medical (NASDAQ:OM) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million. Chemomab Therapeutics (NASDAQ:CMMB) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million. Titan Pharma (NASDAQ:TTNP) shares moved u

EYPT: -42% | EyePoint Pharmaceuticals shares are trading lower after the company's Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint. TCBP: 108% | XBP Europe Holdings shares are trading higher after the company announced it was awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty's Passport Office. FRPT: 15% | Freshpet shares are trading higher after the company reported better-than-expected Q1 financial results.

Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumorsEDINBURGH, Scotland, May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.This agreement is the second such agreement

Gainers Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. Mustang Bio (NASDAQ:MBIO) stock increased by 11.97% to $0.43. The company's market cap stands at $4.4 million. SINTX Techs (NASDAQ:SINT) stock rose 10.32% to $0.04. The market value of their outstanding shares is at $5.0 million. Fortress Biotech (NASDAQ:FBIO) stock moved upwards by 6.21% to $1.88. The market value of their outstanding shares is at $36.1 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 5.92% to $1.43. The company's market cap stands at $4.5 million. Acutus Medical (NASDAQ:AFIB) shares moved upwards by

Gainers Etao International Co (NASDAQ:ETAO) stock moved upwards by 96.6% to $4.9 during Monday's regular session. The company's market cap stands at $25.0 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 48.63% to $3.27. The market value of their outstanding shares is at $8.2 million. Adlai Nortye (NASDAQ:ANL) stock rose 47.3% to $12.21. The market value of their outstanding shares is at $450.3 million. Onconetix (NASDAQ:ONCO) stock moved upwards by 26.56% to $0.21. The company's market cap stands at $4.6 million. MSP Recovery (NASDAQ:LIFW) stock rose 24.42% to $1.63. The market value of their outstanding shares is at $24.1 million. Outset Medical (NASDAQ:OM) shares moved upwa